Clinical Trial Update: A Study of Avutometinib (VS-6766) and Defactinib in People With Mesonephric Gynecologic Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Avutometinib (VS-6766) in combination with Defactinib for mesonephric Gynecologic Cancer; recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mesonephric Gynecologic Cancer

Drugs mentioned

• Avutometinib (VS-6766) (Avutometinib)
• Defactinib (defactinib)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Mesonephric Gynecologic Cancer | Phase 2 | Status: RECRUITING